*Disseminated on Behalf of Nexalin Technology, Inc. Please see disclosures below. |
| Keep an Eye on Nexalin Technology... |
| | | | | Folks, Mental health has become a global epidemic—and despite billions spent on pharmaceuticals each year, millions of patients remain trapped in cycles of medication that often come with dangerous side effects, addiction risks, and limited efficacy.
One small company believes it has developed a drug-free alternative to help treat conditions ranging from insomnia to Alzheimer's disease.
Nexalin Technology (NXL) has built a neurostimulation platform that the company claims delivers 15 times more power than current devices. | | | The Scale of the Problem
The numbers behind mental health disorders are staggering. The global patient populations include:
✓ Insomnia: 850 million patients worldwide
✓ Anxiety: 360 million patients
✓ Depression: 330 million patients
✓ TBI/PTSD: 350 million patients
✓ Alzheimer's and Dementia: 60 million patients
The combined market opportunity across these conditions exceeds $60 billion annually. Current drug treatments are plagued by low efficacy, dangerous side effects and addiction potential.
Perhaps most telling: 70% of patients say they would prefer a drug-free alternative if one were available.
What Makes Nexalin Different?
At the core of Nexalin's approach is something called Deep Intracranial Frequency Stimulation (DIFS). Unlike existing neurostimulation technologies that operate at 1-1.5 milliamps, Nexalin's devices deliver 15 milliamps—theoretically allowing for deeper penetration into midbrain structures where conditions like depression and anxiety originate. | | | Two Devices, Two Markets
Nexalin is pursuing commercialization through two distinct product lines.
The Gen 2 - SYNC is a clinical device designed for use in medical facilities. It features the company's 15 milliamp waveform technology and has already received regulatory approval in China, Brazil, Oman, and Israel for treating anxiety, depression, and insomnia.
Pilot and pivotal FDA clinical trials are expected to begin in the United States.
The Gen 3 - HALO represents a potentially larger opportunity—a wearable headset that allows patients to receive treatment at home under physician supervision through a virtual clinic model. The company has filed FDA Q-submissions and expects to submit its FDA application in 2026. | | | Global Expansion Already Underway
Rather than waiting for FDA clearance to generate revenue, Nexalin has pursued an international-first strategy through joint ventures and regulatory approvals in multiple regions.
Current international clearances include:
✓ China (NMPA): Depression and insomnia
✓ Brazil (ANVISA): Anxiety, depression, and insomnia
✓ Oman (Ministry of Health): Anxiety, depression, and insomnia
✓ Israel (Ministry of Health): Anxiety, depression, and insomnia
The company estimates a $1 billion global market opportunity across these regions and plans to expand further as additional regulatory approvals are secured. |  | Building an IP Moat
For a medical device company, intellectual property protection is critical. Nexalin reports it has built a growing patent portfolio with coverage extending through 2036.
The IP position includes:
✓ 7 patents issued in the United States
✓ 21 patents pending across 14+ countries and regions
✓ Coverage spanning multi-channel electrostimulation, general TACs, mood disorder applications, and Alzheimer's treatment
✓ Design registrations and trademarks pending | | | Near-Term Catalysts
Several developments could affect Nexalin in the coming quarters:
✓ Pilot and pivotal FDA clinical trials for the Gen 2 - SYNC device
✓ FDA application submission for the Gen 3 - HALO expected in 2026
✓ Continued international revenue from existing joint ventures
✓ Military research initiatives for TBI and PTSD treatment
The company has assembled a Military and Government Advisory Board that includes General Wesley Clark (former NATO Supreme Allied Commander) and representatives from the Department of Defense and Veterans Affairs. |  | Worth a Closer Look?
Nexalin represents an interesting case study in addressing mental health through non-pharmaceutical means. The company has built international revenue streams while pursuing FDA approval, assembled clinical data across multiple indications, and developed a patent portfolio to protect its technology.
For those interested in medical device companies targeting the growing mental health market, NXL may be worth monitoring as clinical trials progress and regulatory milestones approach.
Anyways...
That's all for now!
Until Next Time, -ZT Team | P.S. Want our text alerts? Text "ZIPTRADER" to 1-(855)-228-1598 to sign up!
(standard carrier data/text rates apply) |
|
|
|---|
|
*Disseminated on Behalf of Nexalin Technology, Inc. Please see disclosures below. |
|
|---|
|
| | 5101 SANTA MONICA BLVD STE 8 #62, 90029, LOS ANGELES, CA |
| You've received it because you've subscribed to our newsletter or are a member of ZipTraderU. |
| This email was sent to stevenmagallanes520.nims@blogger.com |
| *SPONSORED CONTENT* ZipTrader LLC is a publishing company, we are not financial advisors. This is not financial advice. Investments involve risk and are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance. ZipTrader has been compensated thirty-four thousand USD by ACH Bank Transfer by TD Media LLC to distribute media via email, SMS, and YouTube on behalf of Nexalin Technology, Inc. (NXL) from February 4, 2026 to February 5, 2026. ZipTrader may receive additional campaigns in the future by TD Media LLC to distribute media for Nexalin Technology, Inc. (NXL). As a result of this advertisement and other marketing efforts, ZipTrader may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of ZipTrader do not hold a position in Nexalin Technology, Inc. (NXL). This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Nexalin Technology, Inc. (NXL), increased trading volume, and possibly an increased share price of Nexalin Technology, Inc. (NXL), which may or may not be temporary and decrease once the marketing arrangement has ended. |
| BY READING THIS EMAIL & ALL ZIPTRADER CONTENT YOU AGREE: This is not financial advice. You must do your own due diligence on all information. ZIPTRADER LLC is a publishing company and we provide general information, opinions, & news coverage to viewers. However – we do not provide personalized financial advice, are not financial advisors, and our opinions are not suitable for all investors. You should not treat any opinion as expressed as a specific inducement to make a particular investment or follow a particular strategy, but just as an opinion. Use at your own risk. Past Performance is not indicative of future results, and any results presented are not typical, and should not be understood as typical. Actual results vary given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. TRADING IS RISKY: Most traders in all markets lose all of their money (and more if they use margin). Most small businesses fail. Do NOT partake in trading, investing, entrepreneurship or any other risky endeavor covered here if you are not prepared with the reality that most fail. We reserve the right to have affiliate relationships with advertisers/sponsors. See Full Terms of Service. See Our Advertisement Disclaimer. |
| | |
|
|
|---|
|
|
|
No comments:
Post a Comment